[Gestagen therapy in bladderneck adenoma. III. Clinicochemical findings and course controls in patients with bladderneck adenomas under gestagen therapy].
It is reported on clinico-chemical examinations in 30 carriers of adenomas, who underwent a gestagen therapy lasting 3 months. The treatment was performed in group I in 15 patients with progesterone depot and in group II with depostate. After the end of the treatment in group I an increase of the content of the sodium ions was found. The infections of the urinary tract improved. Neither in negative sense nor in positive sense an influence of the therapy on the other examination parameters was found.
D000236:Adenoma / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D000368:Aged; D001806:Blood Urea Nitrogen; D003404:Creatinine / Q000097:blood; D006801:Humans; D006908:Hydroxyprogesterones / Q000008:administration & dosage*; D007962:Leukocytes / Q000032:analysis; D008875:Middle Aged; D010744:Phosphoric Monoester Hydrolases / Q000097:blood; D011507:Proteinuria / Q000175:diagnosis; D014527:Uric Acid / Q000097:blood; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000652:urine
D006908:Hydroxyprogesterones; D014527:Uric Acid; D003404:Creatinine; D010744:Phosphoric Monoester Hydrolases
Gestagenbehandlung beim Blasenhalsadenom. III. Klinisch-chemische Befunde und Verlaufskontrollen bei Blasenhals-adenomträgern unter Gestagentherapie.